Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner EM, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O. Finke J, et al. Among authors: grishina o. Bone Marrow Transplant. 2024 Aug;59(8):1204. doi: 10.1038/s41409-024-02274-7. Bone Marrow Transplant. 2024. PMID: 38654115 Free PMC article. No abstract available.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: grishina o. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: grishina o. Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17. Biol Blood Marrow Transplant. 2012. PMID: 22713691 Free article. Clinical Trial.
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G. Finke J, et al. Among authors: grishina o. Lancet Haematol. 2017 Jun;4(6):e293-e301. doi: 10.1016/S2352-3026(17)30081-9. Lancet Haematol. 2017. PMID: 28583289 Clinical Trial.
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, Duyster J, Finke J, Zeiser R. von Bubnoff N, et al. Among authors: grishina o. BMC Cancer. 2018 Nov 19;18(1):1132. doi: 10.1186/s12885-018-5045-7. BMC Cancer. 2018. PMID: 30453910 Free PMC article. Clinical Trial.
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Finke J, Schmoor C, Stelljes M, Burchert A, Dreger P, Hegenbart U, Wagner-Drouet EM, Bornhäuser M, Sohlbach K, Schub N, Reicherts C, Kobbe G, Glass B, Bertz H, Grishina O. Finke J, et al. Among authors: grishina o. Bone Marrow Transplant. 2022 Nov;57(11):1664-1670. doi: 10.1038/s41409-022-01777-5. Epub 2022 Aug 18. Bone Marrow Transplant. 2022. PMID: 35982219 Free PMC article. Clinical Trial.
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study).
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner EM, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O. Finke J, et al. Among authors: grishina o. Bone Marrow Transplant. 2024 Jul;59(7):936-941. doi: 10.1038/s41409-024-02264-9. Epub 2024 Mar 16. Bone Marrow Transplant. 2024. PMID: 38493275 Free PMC article. Clinical Trial.
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.
Thomas J, Rehman UU, Bresser H, Grishina O, Pfeifer D, Sollier E, Döhner K, Plass C, Becker H, Schmoor C, de Wit M, Lübbert M. Thomas J, et al. Among authors: grishina o. Clin Epigenetics. 2024 Sep 11;16(1):126. doi: 10.1186/s13148-024-01737-4. Clin Epigenetics. 2024. PMID: 39261919 Free PMC article.
46 results